NURIX THERAPEUTICS, INC. Proceeds from Issuance of Redeemable Convertible Preferred Stock
NURIX THERAPEUTICS, INC. (NRIX) reported Proceeds from Issuance of Redeemable Convertible Preferred Stock of $119.91 million for the 12-month period ending 2020-11-30, per its 10-K filed 2022-01-28.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock · last filed 2022-01-28
- NURIX THERAPEUTICS, INC. proceeds from issuance of redeemable convertible preferred stock for the quarter ending 2020-11-30 was $0.00.
- NURIX THERAPEUTICS, INC. proceeds from issuance of redeemable convertible preferred stock for the quarter ending 2020-08-31 was $0.00.
- NURIX THERAPEUTICS, INC. proceeds from issuance of redeemable convertible preferred stock for fiscal 2020 was $119.91M.
| Period end | Proceeds from Issuance of Redeemable Convertible Preferred Stock 3 month | Proceeds from Issuance of Redeemable Convertible Preferred Stock 6 month | Proceeds from Issuance of Redeemable Convertible Preferred Stock 9 month | Proceeds from Issuance of Redeemable Convertible Preferred Stock 12 month |
|---|---|---|---|---|
| 2020-11-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | $0.00 derived: sum of 2 quarters · filed 2022-01-28 | $119.91M 10-K · filed 2022-01-28 | |
| 2020-08-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-14 | $119.91M 10-Q · filed 2021-10-14 | ||
| 2020-05-31 | $119.91M 10-Q · filed 2021-07-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |